Starpharma Holdings Limited · ASX:SPL

Starpharma — Starpharma Pooled Development — Investor Presentation (September 2003)

22 slides from Starpharma's investor presentation, Sep 2, 2003

  1. Slide 1: Presentation - Company Update

    starpharma 2% September 2003 STARPHARMA POOLED DEVELOPMENT LTD (ASX:SPL) PRESENTATION - COMPANY UPDATE Attached is a presentation - Company Update - which will be made available on the Company's website. Ben Régers compen ee etary Starpharma Pooled Development Limited (SPL) is a registered pooled de

  2. Slide 2: Leading the World in Nanomedicine

    starpharma . leading the World in nanomedicine... September 2003 www. starpharma.com

  3. Slide 3: Overview

    Overview starp nari

  4. Slide 4: Background to Starpharma

    Background to Starpharma starpharma

  5. Slide 5: Achievements Since Listing on ASX

    Achievements Since Listing on ASX starpharma

  6. Slide 6: Rapidly Growing Interest in Dendrimer Technology

    Rapidly Growing Interest in Dendrimer Technology starpharma

  7. Slide 7: Polyvalence & Dendrimers as Drugs

    Polyvalence & Dendrimers as Drugs r starpharma

  8. Slide 8: GlaxoSmithKline/Theravance US$545m

    GlaxoSmithKline/Theravance US$545m starp nari

  9. Slide 9: Intellectual Property

    ea. Intellectual Property r starpharma

  10. Slide 10: R&D Pipeline

    R&D Pipeline r starpharma

  11. Slide 11: VivaGel Drug Product

    VivaGel™ Drug Product Photo: Nature Reviews Drug Discovery 2002, pg 977 10 starp nari

  12. Slide 12: VivaGel Prevents SHIV Infection in Macaques

    VivaGel™ Prevents SHIV Infection in Macaques 11 starp nari

  13. Slide 13: VivaGel Clinical Trial Strategy

    VivaGel™ Clinical Trial Strategy 12 starp nari

  14. Slide 14: Respiratory

    ea. Respiratory 13 r starpharma

  15. Slide 15: Oncology

    Oncology r starpharma 14

  16. Slide 16: Exotic Diseases

    ea. Exotic Diseases 15 starp nari

  17. Slide 17: Starpharma PDL - US Investment

    Starpharma PDL — US Investment r starpharma 16

  18. Slide 18: DNT - Objectives

    DNT - Objectives r starpharma 17

  19. Slide 19: DNT - Key Achievements

    DNT — Key Achievements 18 starp arma

  20. Slide 20: DNT - Key Assets and Relationships

    DNT — Key Assets and Relationships SIGMA- ALORICH FIME CHEMICALS

  21. Slide 21: Starpharma - Future Opportunities

    Starpharma - Future Opportunities 20 starpharma

  22. Slide 22: Leading the World in Nanomedicine

    harma ..deading the World in nanomedicine... star September 2003 www. starpharma.com

Starpharma Pooled Development — Investor Presentation (September 2003) on 6ix